摘要

The use of induction chemotherapy (CT) is controversial. We compared the survival of head and neck cancer patients receiving docetaxel-or platinum-based induction CT before concomitant chemoradiotherapy (CCRT) with the survival of those receiving upfront CCRT alone. Data fromtheNationalHealth Insurance and cancer registry databases in Taiwan were linked and analyzed. We enrolled patients who had head and neck cancer between January 1, 2002andDecember 31, 2011. Followup was from the index date to December 31, 2013.We included head and neck patients diagnosed according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9 who were aged
原文英語
頁(從 - 到)e2845
期刊Medicine (United States)
95
發行號7
DOIs
出版狀態已發佈 - 2016

指紋

Induction Chemotherapy
Head and Neck Neoplasms
Taiwan
docetaxel
Chemoradiotherapy
Survival
International Classification of Diseases
Platinum
Insurance
Registries
Neck
Head
Databases
Neoplasms

引用此文

@article{a99974238eba44a8945f44befab889bb,
title = "Outcomes of induction chemotherapy for head and neck cancer patients a combined study of two national cohorts in Taiwan",
abstract = "The use of induction chemotherapy (CT) is controversial. We compared the survival of head and neck cancer patients receiving docetaxel-or platinum-based induction CT before concomitant chemoradiotherapy (CCRT) with the survival of those receiving upfront CCRT alone. Data fromtheNationalHealth Insurance and cancer registry databases in Taiwan were linked and analyzed. We enrolled patients who had head and neck cancer between January 1, 2002andDecember 31, 2011. Followup was from the index date to December 31, 2013.We included head and neck patients diagnosed according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9 who were aged",
author = "Jin-Hua Chen and Yu-Chun Yen and Liu, {Shing Hwa} and Yuan, {Sheng Po} and Wu, {Li Li} and Fei-Peng Lee and Lin, {Kuan Chou} and Ming-Tang Lai and Chia-Che Wu and Chen, {Tsung Ming} and Chang, {Chia Lun} and Jyh-Ming Chow and Ding, {Yi Fang} and Ming-Chin Lin and Szu-Yuan Wu",
note = "Export Date: 29 March 2016 CODEN: MEDIA 通訊地址: Wu, S.-Y.; Institute of Toxicology, College of Medicine, National Taiwan UniversityTaiwan; 電子郵件: szuyuanwu5399@gmail.com 參考文獻: Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013 (2013) CA Cancer J Clin., 63, pp. 11-30; (2011) Health Promotion Administration MoHaW: Taiwan Cancer Registry Report, 2011 Edition, , Health Promotion Administration, Ministry of Health and Welfare; Pointreau, Y., Garaud, P., Chapet, S., Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation (2009) J Natl Cancer Inst., 101, pp. 498-506; Pignon, J.P., Le Maitre, A., Maillard, E., Meta-analysis of chemotherapy in head and neck cancer (Mach-NC): An update on 93 randomised trials and 17, 346 patients (2009) Radiother Oncol., 92, pp. 4-14; Posner, M.R., Hershock, D.M., Blajman, C.R., Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer (2007) N Engl J Med., 357, pp. 1705-1715; Vermorken, J.B., Remenar, E., Van Herpen, C., Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (2007) N Engl J Med., 357, pp. 1695-1704; Haddad, R., O'Neill, A., Rabinowits, G., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemora-diotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial (2013) Lancet Oncol., 14, pp. 257-264; Cohen, E.E., Karrison, T.G., Kocherginsky, M., Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer (2014) J Clin Oncol., 32, pp. 2735-2743; Charlson, M., Szatrowski, T.P., Peterson, J., Validation of a combined comorbidity index (1994) J Clin Epidemiol., 47, pp. 1245-1251; Chow, S., Wang, H., Shao, J., (2008) Sample Size Calculations in Clinical Research. 2nd Ed, p. 177. , New York: Chapman and Hall/CRC; Forastiere, A.A., Goepfert, H., Maor, M., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer (2003) N Engl J Med., 349, pp. 2091-2098; Adelstein, D.J., Li, Y., Adams, G.L., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squa-mous cell head and neck cancer (2003) J Clin Oncol., 21, pp. 92-98; Calais, G., Alfonsi, M., Bardet, E., Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma (1999) J Natl Cancer Inst., 91, pp. 2081-2086; Domenge, C., Hill, C., Lefebvre, J.L., Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC) (2000) Br J Cancer., 83, pp. 1594-1598; Zorat, P.L., Paccagnella, A., Cavaniglia, G., Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up (2004) J Natl Cancer Inst., 96, pp. 1714-1717; Paccagnella, A., Orlando, A., Marchiori, C., Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo (1994) J Natl Cancer Inst., 86, pp. 265-272; Pignon, J.P., Bourhis, J., Domenge, C., Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Mach-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer (2000) Lancet., 355, pp. 949-955; Hitt, R., Grau, J.J., Lopez-Pousa, A., A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer (2014) Ann Oncol., 25, pp. 216-225; Takacsi-Nagy, Z., Hitre, E., Remenar, E., Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiother-apy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study (2015) Strahlenther Onkol., 191, pp. 635-641; Paccagnella, A., Ghi, M.G., Loreggian, L., Concomitant chemor-adiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study (2010) Ann Oncol., 21, pp. 1515-1522; Posner, M.R., Lorch, J.H., Goloubeva, O., Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial (2011) Ann Oncol., 22, pp. 1071-1077; Liao, C.T., Wallace, C.G., Lee, L.Y., Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area (2014) Oral Oncol., 50, pp. 721-731; Liao, C.T., Kang, C.J., Chang, J.T., Survival of second and multiple primary tumors in patients with oral cavity squamous cell carcinoma in the betel quid chewing area (2007) Oral Oncol., 43, pp. 811-819; Corry, J., Peters, L., Kleid, S., Larynx preservation for patients with locally advanced laryngeal cancer (2013) J Clin Oncol., 31, pp. 840-844; Balermpas, P., Bauer, C., Fraunholz, I., Concomitant chemora-diotherapy versus induction chemotherapy followed by chemora-diotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis (2014) Strahlenther Onkol., 190, pp. 256-262; Lefebvre, J.L., Pointreau, Y., Rolland, F., Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study (2013) J Clin Oncol., 31, pp. 853-859; Faivre, S., Albert, S., Raymond, E., Induction chemotherapy challenges for head and neck cancer (2013) Lancet Oncol., 14, pp. 188-189",
year = "2016",
doi = "10.1097/MD.0000000000002845",
language = "English",
volume = "95",
pages = "e2845",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Outcomes of induction chemotherapy for head and neck cancer patients a combined study of two national cohorts in Taiwan

AU - Chen, Jin-Hua

AU - Yen, Yu-Chun

AU - Liu, Shing Hwa

AU - Yuan, Sheng Po

AU - Wu, Li Li

AU - Lee, Fei-Peng

AU - Lin, Kuan Chou

AU - Lai, Ming-Tang

AU - Wu, Chia-Che

AU - Chen, Tsung Ming

AU - Chang, Chia Lun

AU - Chow, Jyh-Ming

AU - Ding, Yi Fang

AU - Lin, Ming-Chin

AU - Wu, Szu-Yuan

N1 - Export Date: 29 March 2016 CODEN: MEDIA 通訊地址: Wu, S.-Y.; Institute of Toxicology, College of Medicine, National Taiwan UniversityTaiwan; 電子郵件: szuyuanwu5399@gmail.com 參考文獻: Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013 (2013) CA Cancer J Clin., 63, pp. 11-30; (2011) Health Promotion Administration MoHaW: Taiwan Cancer Registry Report, 2011 Edition, , Health Promotion Administration, Ministry of Health and Welfare; Pointreau, Y., Garaud, P., Chapet, S., Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation (2009) J Natl Cancer Inst., 101, pp. 498-506; Pignon, J.P., Le Maitre, A., Maillard, E., Meta-analysis of chemotherapy in head and neck cancer (Mach-NC): An update on 93 randomised trials and 17, 346 patients (2009) Radiother Oncol., 92, pp. 4-14; Posner, M.R., Hershock, D.M., Blajman, C.R., Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer (2007) N Engl J Med., 357, pp. 1705-1715; Vermorken, J.B., Remenar, E., Van Herpen, C., Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (2007) N Engl J Med., 357, pp. 1695-1704; Haddad, R., O'Neill, A., Rabinowits, G., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemora-diotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial (2013) Lancet Oncol., 14, pp. 257-264; Cohen, E.E., Karrison, T.G., Kocherginsky, M., Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer (2014) J Clin Oncol., 32, pp. 2735-2743; Charlson, M., Szatrowski, T.P., Peterson, J., Validation of a combined comorbidity index (1994) J Clin Epidemiol., 47, pp. 1245-1251; Chow, S., Wang, H., Shao, J., (2008) Sample Size Calculations in Clinical Research. 2nd Ed, p. 177. , New York: Chapman and Hall/CRC; Forastiere, A.A., Goepfert, H., Maor, M., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer (2003) N Engl J Med., 349, pp. 2091-2098; Adelstein, D.J., Li, Y., Adams, G.L., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squa-mous cell head and neck cancer (2003) J Clin Oncol., 21, pp. 92-98; Calais, G., Alfonsi, M., Bardet, E., Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma (1999) J Natl Cancer Inst., 91, pp. 2081-2086; Domenge, C., Hill, C., Lefebvre, J.L., Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC) (2000) Br J Cancer., 83, pp. 1594-1598; Zorat, P.L., Paccagnella, A., Cavaniglia, G., Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up (2004) J Natl Cancer Inst., 96, pp. 1714-1717; Paccagnella, A., Orlando, A., Marchiori, C., Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo (1994) J Natl Cancer Inst., 86, pp. 265-272; Pignon, J.P., Bourhis, J., Domenge, C., Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Mach-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer (2000) Lancet., 355, pp. 949-955; Hitt, R., Grau, J.J., Lopez-Pousa, A., A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer (2014) Ann Oncol., 25, pp. 216-225; Takacsi-Nagy, Z., Hitre, E., Remenar, E., Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiother-apy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study (2015) Strahlenther Onkol., 191, pp. 635-641; Paccagnella, A., Ghi, M.G., Loreggian, L., Concomitant chemor-adiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study (2010) Ann Oncol., 21, pp. 1515-1522; Posner, M.R., Lorch, J.H., Goloubeva, O., Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial (2011) Ann Oncol., 22, pp. 1071-1077; Liao, C.T., Wallace, C.G., Lee, L.Y., Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area (2014) Oral Oncol., 50, pp. 721-731; Liao, C.T., Kang, C.J., Chang, J.T., Survival of second and multiple primary tumors in patients with oral cavity squamous cell carcinoma in the betel quid chewing area (2007) Oral Oncol., 43, pp. 811-819; Corry, J., Peters, L., Kleid, S., Larynx preservation for patients with locally advanced laryngeal cancer (2013) J Clin Oncol., 31, pp. 840-844; Balermpas, P., Bauer, C., Fraunholz, I., Concomitant chemora-diotherapy versus induction chemotherapy followed by chemora-diotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis (2014) Strahlenther Onkol., 190, pp. 256-262; Lefebvre, J.L., Pointreau, Y., Rolland, F., Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study (2013) J Clin Oncol., 31, pp. 853-859; Faivre, S., Albert, S., Raymond, E., Induction chemotherapy challenges for head and neck cancer (2013) Lancet Oncol., 14, pp. 188-189

PY - 2016

Y1 - 2016

N2 - The use of induction chemotherapy (CT) is controversial. We compared the survival of head and neck cancer patients receiving docetaxel-or platinum-based induction CT before concomitant chemoradiotherapy (CCRT) with the survival of those receiving upfront CCRT alone. Data fromtheNationalHealth Insurance and cancer registry databases in Taiwan were linked and analyzed. We enrolled patients who had head and neck cancer between January 1, 2002andDecember 31, 2011. Followup was from the index date to December 31, 2013.We included head and neck patients diagnosed according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9 who were aged

AB - The use of induction chemotherapy (CT) is controversial. We compared the survival of head and neck cancer patients receiving docetaxel-or platinum-based induction CT before concomitant chemoradiotherapy (CCRT) with the survival of those receiving upfront CCRT alone. Data fromtheNationalHealth Insurance and cancer registry databases in Taiwan were linked and analyzed. We enrolled patients who had head and neck cancer between January 1, 2002andDecember 31, 2011. Followup was from the index date to December 31, 2013.We included head and neck patients diagnosed according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9 who were aged

U2 - 10.1097/MD.0000000000002845

DO - 10.1097/MD.0000000000002845

M3 - Article

VL - 95

SP - e2845

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 7

ER -